Study of two drugs for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (which blocks blood vessel growth to tumors)—for people whose glioblastoma has returned after standard treatment. The goal is to see if this combo can slow or stop the cancer with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of glioblastoma (a type of brain cancer).
- You should have had surgery at Henan Provincial People's Hospital, with a small port placed under the scalp to collect fluid from the surgery area.
- You must have completed radiation therapy as your first treatment at least 28 days before joining.
- You need to be in fairly good health, able to care for yourself (Karnofsky score of 70 or higher), and expected to live more than 12 weeks.
- You cannot have had more than one recurrence of the cancer, and it must not have spread outside the brain.
- You must not have taken certain previous treatments like bevacizumab, PD-1/PD-L1 inhibitors, or CTLA-4 inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial tests a more intense chemotherapy plan for people with glioblastoma who had only partial removal of their tumor or whose tumor grew back quickly. The goal is to see if this approach can improve outcomes.
This trial tests a new combination of two drugs, entacapone and bevacizumab, for people whose glioblastoma (a type of brain tumor) has returned after initial treatment. The goal is to see if this combination can help control the tumor and improve outcomes.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.